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http:WHAT THIS PAPER ADDS
This study evaluated the effect of systemically administered urokinase (UK) for 5 days after percutaneous
transluminal angioplasty with or without stent on the reduction of the rate and level of amputation in patients
with critical limb ischemia (CLI) with tissue loss. It was postulated that patients with CLI may have increased clot
load at tissue level due to decreased ﬂow with diseased pedal arteries, and embolization due to the inter-
vention. The results showed that systemic administration of UK may reduce the requirement for major am-
putations (especially for infrapopliteal interventions). However, these ﬁndings need to be conﬁrmed in a
randomized prospective study.Objective: To evaluate the effect of systemically administered urokinase (UK) after percutaneous transluminal
angioplasty with or without stent (PTA  stent) on the reduction in the rate and level of amputation in patients
with critical limb ischemia (CLI) with tissue loss.
Methods: This was an observational, nonrandomized, retrospective study of 183 Taiwanese patients with
Rutherford stage 5 or 6, and Fontaine stage 4 lower extremity CLI. Patients received either PTA  stent or
PTA  stent þ UK infusion (250,000 IU, daily for 5 days). PTA of the iliac, femoral, anterior tibial artery, posterior
tibial artery, and peroneal arterieswas included. Amputationwas classiﬁed asminor, with direct wound healing, and
minor amputation or surgical debridement of toes andmajor, with below- (BKA) and above-knee amputation (AKA).
Results: In groups of patients with comparable baseline characteristics, 85 and 90 patients received PTA  stent
and PTA  stent þ UK, respectively. There were 24 major limb amputations performed. A signiﬁcant majority
(20/24 (83.3%) were performed in patients who did not receive adjuvant urokinase, compared with 4/24 (16.7%)
of patients who did receive urokinase (p ¼ 0.000287). There was a signiﬁcant increase in the limb salvage rate for
infrapopliteal lesions in patients treated with PTA þ UK (12/72 with UK; 60/72 without UK; p  .0001).
Intracranial hemorrhage (n ¼ 1) and bleeding at the inguinal puncture site (n ¼ 2) were reported in the
PTA  stent þ UK group. Eight deaths (one in the PTA  stent þ UK group; seven in the PTA  stent) occurred
during the study.
Conclusion: Systemic administration of UK with the PTA  stent procedure may reduce the requirement for
major amputation in patients with CLI with tissue loss (Rutherford 5 or 6). The difference is more pronounced in
patients undergoing infrapopliteal interventions. However, these ﬁndings need to be conﬁrmed in a randomized
prospective study.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2014.04.006procedure for lower limb atherosclerosis.1 Femoropopliteal
and infrapopliteal interventions have been increasingly used
in the last decade, especially in patients with signiﬁcant
comorbidities,2,3 and in those who have acute or subacute
presentations with signiﬁcant clot loads in their occluded
arterial segments.4e6 Signiﬁcant microembolization occurs
during endovascular interventions, most of which goes
undetected.7 In some studies, low-dose systemic urokinase
(UK) was used alone, without any intervention in patients
with diabetes in order to improve microcirculation and
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be an increased clot load at the microcirculation level in
these patients.8,9 It was postulated that patients with crit-
ical limb ischemia (CLI) may have increased clot load at
tissue level due to decreased ﬂow with diseased pedal ar-
teries, and embolization due to the intervention. Therefore,
use of systemic UK as an adjunctive method to improve
blood ﬂow at the tissue level following endovascular in-
terventions was planned to theoretically decrease the clot
load at tissue level.
Here, the ﬁndings of a large, preliminary, observational,
retrospective study that evaluated the effect of infusion of
UK after PTA  stent in patients with CLI with tissue loss on
the rate of limb salvage are reported.MATERIALS AND METHODS
Study design
This observational, nonrandomized, retrospective study
evaluated patients with CLI with tissue loss from June 2009
to May 2012 in Kaohsiung Chang Gung Memorial Hospital,
Taiwan. The patients were divided into two groups. The ﬁrst
group received PTA  stent, while the second was treated
with PTA  stent followed by the systemic intravenous (IV)
infusion of UK (PTA  stent þ UK). The administration of UK
was initiated in March 2010; therefore, the ﬁrst 50 patients
treated and included in the study did not receive UK.
Thereafter, all patients were treated with UK; however,
patients with a contraindication to UK or those who did not
consent to the use of UK were placed in the PTA  stent
group. All patients were treated with either balloon an-
gioplasty only and/or with a bail-out stent following balloon
angioplasty.Patients
Adult male or female patients with CLI with tissue loss of the
lower extremity (Rutherford classiﬁcation stage 5 or 6, and
Fontaine classiﬁcation stage 4) were included.1,10,11 Patients
with angiopathic or angioneuropathic diabetic foot lesions,
limbswith poorwound healing status afterminor amputation
of foot or toes, and foot wounds caused by angiopathy
(conﬁrmed by angiography) were also included if they had an
ankleebrachial index (ABI) of <0.7 (without uncontrolled
hypertension) or severely calciﬁed vessels with ABI of >1.5
(where stenosis cannot be evaluated), a dampened or
partially pulsatile pulseevolume curve, and/or existing toes
that were silent or partially pulsatile. Patients were excluded
from PTA  stent þ UK if the infusion of UK was contra-
indicated, such as in those with untreated proliferative reti-
nopathy, an allergy to UK, a cerebrovascular episode within 6
months, uncontrolled hypertension, hemorrhagic diathesis, a
plasma ﬁbrinogen level <200 mg/dL, or gastrointestinal
bleeding within 3 months. Other exclusion criteria included
the need for oral anticoagulation, mental disorders, preg-
nancy, or participation in another study. Patients with
neuropathic diabetic foot lesions without angiopathy were
also excluded after angiography.Treatments
PTA procedure. Balloon angioplasty was performed using a
Paciﬁc 0.018 wire system (Medtronic Invatec, Minneapolis,
MN, USA) or ATB ADVANCE 0.35 wire system (Cook Medical,
Bloomington, IN, USA). The catheter was inserted to the site
of narrowing through a routine contralateral femoral punc-
ture with retrograde crossover access. Diagnostic angiog-
raphy was performed to conﬁrm the target lesion and the
choice of treatment. If the sheath was able to pass beyond
the lesions in the iliac or superﬁcial femoral arteries (SFA), the
lesion below the knee was treated ﬁrst to achieve, at least, a
two-vessel distal runoff. The SFA or iliac lesions were treated
thereafter. In all cases, we treated the infrapopliteal lesion
ﬁrst, exceptwhen therewas a total occlusion of the SFA. After
clearing the infrapopliteal occlusion, the SFA segment was
treated to ensure good distal runoff. If possible, antegrade
and retrograde ﬂow was assessed using the angiosome
concept to create at least two distal runoff vessels (>90%
patients). At least one distal runoff was achieved in the
remaining cases. A stent (Life stent [Bard PV,Tempe, AZ, USA];
Zilver stent [Cook Medical]; or Maris stent [Medtronic, Min-
neapolis, MN, USA]) was placed, if considered needed. These
stents were mostly bail-out stents for balloon angioplasty
causing focal dissection or limited ﬂow or recoil with 50%
residual stenosis in the SFA. However, a repeat balloon an-
gioplasty was performed for the below-knee arteries. To
assess the limited residual stenosis in the iliac or SFA, and to
conﬁrm the two-vessel distal runoff in the below-knee ar-
teries, the result of the PTA procedure was checked by a ﬁnal
angiography. Assessments of wound healing and distal pul-
sation (using hand-held Doppler) were performed daily dur-
ing the period of hospitalization. If poor progression of
wound healing was observed, ABI was repeated after 2
weeks. If the pulse signal was absent, angiography was
repeated to conﬁrm patency of the target lesion. Based on
the angiographic ﬁndings, endovascular treatment options
were assessed by multidisciplinary consensus among angi-
ologists, vascular surgeons, and interventionalists. Minor
amputation or debridement was carried out in stages, as
required, for the prevention of infection. Thereafter, the de-
cision to perform limb amputation (with possible local rota-
tional ﬂap or intensive wound care), with the aim of maximal
limb preservation, was undertaken by a team of vascular
surgeons, angioplasty surgeons, and orthopaedic surgeons
after obtaining patient consent. Furthermore, below-knee
amputation (BKA) was performed before above-knee ampu-
tation (AKA). Structured wound care, including wound
debridement and moist wound dressings, was provided to
every patient. The choice of moist dressing was at the
discretion of the surgeon. Patient follow-up lasted until
complete healing of the wound was observed or until major
amputation was required. The length of hospital stay was
recorded.IV infusion of UK and concomitant medications
Systemic IV UK (Urokinase-GCC Injection 250,000 IU [Green
Cross Corporation, Yongin, Korea]) was administered daily
416 H.-T. Yen et al.for 5 days after PTA  stent. The dose of UK was based on
the levels of plasma ﬁbrinogen (if ﬁbrinogen was >300 mg/
dL, the dose of UK was 1.5  106 IU/day; if it was 200e
300 mg/dL, the dose of UK was 1.0  106 IU/day; if it was
150e200 mg/dL, the dose of UK was 0.5  106 IU/day; and
if it was <150 mg/dL, the administration of UK was
stopped). The levels of both hemoglobin and ﬁbrinogen
were assessed daily and formed the basis for dose
adjustment.
Periprocedural medication included the use of heparin
(5,000 IU intra-arterial injection), which was repeated every
4 hours. In addition to the 5 days of IV UK infusion,
catheter-directed thrombolysis (250,000 IU UK dilution in
normal saline 20 mL) with/without thrombus aspiration was
performed if a thrombus was noted during the procedure.
The dose was adjusted by monitoring daily ﬁbrinogen
levels. No patient received either a drug-eluting balloon,
stent, or atherectomy device. Concomitant medications in
patients with stents included clopidogrel 75 mg four times
daily with cilostazol 50e100 mg twice daily, and in patients
without stents acetylsalicylic acid 100 mg with cilostazol
50e100 mg twice daily.Evaluation of amputation
Amputations were grouped as minor and major. The former
included direct wound healing, no amputation, minor sur-
gical debridement, or minor amputation of toes; the latter
included BKA (stump, 10 cm) and above-knee amputation
(AKA).Assessments and outcomes
The PTA procedure was performed on the iliac, femoral,
anterior tibial artery (ATa), posterior tibial artery (PTa), and
peroneal arteries, and its efﬁcacy was evaluated by angi-
ography. Stents, mostly bail-out, were placed when indi-
cated. Pressure indices in the lower extremity (thigh, calf,
PTa, and dorsalis pedis [ABI]) were assessed for diagnosis
and treatment, and for monitoring prognosis. Laboratory
evaluation included hemoglobin A1c, blood urea nitrogen,
creatinine, creatinine clearance, white blood cell count,
hemoglobin, ﬁbrinogen, and platelet count. Ischemic eval-
uation and the decision to amputate or offer surgical bypassTable 1. Patient demographics and baseline characteristics.
PTA  stent
Characteristic
Number of patients (n) 85
Female (%) 50.5
Age (years)
Mean (SD) 71.04 (10.10)
Median 72.0
Range (min., max.) 49, 91
Limb (%)
Left leg 37.6
Right leg 62.4
Wound (%) 100were based on the clinical evaluation of the limb, pressure
indices, arterial duplex scan, and angiography. Levels of
amputation were assessed along with their relationship
with comorbid conditions such as diabetes mellitus (DM),
hypertension, end-stage renal disease (ESRD), coronary ar-
tery disease (CAD), cerebrovascular accidents (CVAs), and
dyslipidemia. The duration of hospital stay was also
evaluated.
Safety
Safety assessments for the infusion of UK were based on
monitoring daily ﬁbrinogen levels. The type, frequency,
severity, and relationship of adverse events, treatment-
emergent adverse events, and serious adverse events
(SAEs) to the treatments administered were compared be-
tween both groups.
Statistical analysis
Continuous and categorical variables were analyzed using
Student t test and Fisher’s exact test, respectively. The odds
ratio (OR) was obtained to evaluate the efﬁcacy endpoint,
and a p-value <.05 was considered to be statistically sig-
niﬁcant. All analyses were performed with SAS version 9.2
(SAS Institute, Cary, NC, USA).
RESULTS
Patient demographics and baseline characteristics
Of the 183 patients that received interventional therapy,
175 (mean age 70.8 years) with CLI of the lower extremity
were allocated into two groups: PTA  stent (85 patients)
and PTA  stent þ UK infusion for 5 days (90 patients).
Eight patients were not included owing to symptoms of
intermittent claudication. Baseline characteristics were
generally comparable between treatment groups, except for
patients with DM and those with peroneal and iliac artery
occlusion (Tables 1 and 2).
Evaluation of the level of amputation between the study
groups
There were 24 major limb amputations performed. A sig-
niﬁcant majority (20/24 (83.3%) were performed in patientsPTA  stent  UK pa
90 1.0000
51.1 e
70.51 (11.52) .7499
72.5 e
32, 94 e
41.1 .6464
58.9 e
100 ND
Table 1-continued
PTA  stent PTA  stent  UK pa
Comorbid condition (%)
DM 92.9 81.1 .0251
Hypertension 98.8 96.7 .6213
ESRD 36.5 43.3 .4403
CAD 44.7 45.6 1.0000
CVA 37.6 25.6 .1037
Dyslipidemia 55.3/85.0 61.1 .4477
Pressure indices
Thigh
Mean (SD) 1.17 (0.37) 1.22 (0.35) .3658
Median 1.22 1.24 e
Range (min., max.) 0.46, 2.51 0.30, 2.03 e
Calf
Mean (SD) 0.75 (0.31) 0.79 (0.35) .4406
Median 0.62 0.70 e
Range (min., max.) 0.26, 1.40 0.16, 1.78 e
PT
Mean (SD) 0.66 (0.32) 0.61 (0.30) .3356
Median 0.56 0.57 e
Range (min., max.) 0.20, 1.65 0.00, 1.72 e
DP
Mean (SD) 0.58 (0.30) 0.56 (0.28) .6563
Median 0.53 0.55 e
Range (min., max.) 0.00, 1.66 0.00, 1.73 e
Laboratory investigationsb,c
HbA1c (%) 7.81 (1.90) 7.83 (1.66) .9504
BUN (mg/dL) 33.83 (23.50) 37.90 (27.45) .2951
Creatinine (mg/dL) 3.38 (3.41) 15.45 (106.30) .2848
Creatinine clearance (mg/dL) 38.49 (24.05) 35.32 (25.91) .4031
WBC count (cells  103/L) 9.27 (3.52) 14.12 (41.51) .2722
Abnormal WBC count (cells  103/L), n (%)
Abnormal 23 (27.1) 29 (32.2) .5097
Normal 62 (72.9) 61 (67.8) e
Hemoglobin (103/L) 10.98 (1.88) 10.72 (1.62) .3181
Abnormal hemoglobin (103/L), n (%)
Abnormal 58 (68.2) 68 (75.6) .3146
Normal 27 (31.8) 22 (24.4) e
Platelet count (cells  103/L) 272.52 (95.90) 277.64 (103.50) .7347
Abnormal platelet count (cells  103/L), n (%)
Abnormal 13 (15.3) 10 (11.1) .5038
Normal 72 (84.7) 80 (88.9) e
Fibrinogen (mg/dL) 424.09 (107.30) 428.33 (106.50) .8679
Length of hospital stay (days)
Mean (SD) 33.60 (19.82) 17.88 (14.54) .0008
Median 30 12 e
Range (min., max.) 5, 62 5, 60 e
Note. PTA ¼ percutaneous transluminal angioplasty; UK ¼ urokinase; DM ¼ diabetes mellitus; ESRD ¼ end-stage renal disease;
CAD ¼ coronary artery disease; CVA ¼ cerebrovascular accident; PT ¼ posterior tibial; DP ¼ dorsalis pedis; HbA1c ¼ hemoglobin A1c;
BUN ¼ blood urea nitrogen; WBC ¼ white blood cell.
a p < .05 was considered to be statistically signiﬁcant.
b The number of patients for which HbA1c was measured was 68 and 73 for the PTA  stent and the PTA  stent þ UK groups,
respectively. The number of patients for which BUN, creatinine, creatinine clearance, WBC count, abnormal WBC count, hemoglobin,
abnormal hemoglobin, platelet count, abnormal platelet count, ﬁbrinogen and length of hospital stay was measured was 85 and 90 for the
PTA  stent and the PTA  stent þ UK groups, respectively.
c All values are given as mean (SD) unless otherwise indicated.
European Journal of Vascular and Endovascular Surgery 417who did not receive adjuvant urokinase, compared with 4/
24 (16.7%) of patients who did receive urokinase (p ¼
0.000287) (Table 3). The decrease in major amputation with
UK was reﬂected by an increase in minor amputations
(Table 3; Fig. 1).Evaluation of the level of amputation versus the site of the
treated arterial lesion
The PTA  stent þ UK regimen led to a signiﬁcant reduction
in major amputation when the treatment procedure
involved the femoral artery (p ¼ .000755). Similar
Table 2A. Evaluation of the treatment procedures between the
treatment groups.
PTA  stent PTA  stent þ UK pa
Arteries (n) 85 90 e
Iliac 1b 24.7 11.1 .0414
2c 3.5 2.2 e
Femoral 1d 42.4 57.8 .0601
2 43.5 26.7 e
ATa 2 43.5 57.8 .0701
PTa 2 34.1 33.3 1.0000
Peroneal 2 18.8 37.8 .0072
Note. PTA ¼ percutaneous transluminal angioplasty;
UK ¼ urokinase; ATa ¼ anterior tibial artery; PTa ¼ posterior
tibial artery.
a P < 0.05 was considered statistically signiﬁcant.
b Primary stenting.
c “2” indicates balloon angioplasty.
d Placement of bail-out stent.
418 H.-T. Yen et al.signiﬁcant reductions were seen with the addition of UK to
PTA only in the ATa (p ¼ .0395), PTa (p ¼ .0203), and
peroneal artery (p ¼ .0047) (Table 4). Patients with arterial
segments containing lesions with <50% stenosis and not
receiving any intervention showed a signiﬁcant reduction in
major amputation in the PTA  stent þ UK group when the
treatment involved the iliac artery (p ¼ 0.0011), ATa
(p ¼ .0366), and PTa regions (p ¼ .0218) (Table 4). Thus,
patients with lesions requiring no intervention also showed
signiﬁcant improvement in amputation level with UK.Evaluation of the levels of amputation versus comorbid
conditions
There was a signiﬁcant reduction in major amputations
when UK was added to PTA  stent in patients with co-
morbid conditions such as DM (p ¼ .0051), hypertension
(p ¼ .000876), ESRD (p ¼ .0063), and CAD (p ¼ .0023)
(Table 5). A signiﬁcant reduction in the number of major
amputations was observed with the addition of UK in pa-
tients without comorbidities such as CVA (episode >6
months ago; p ¼ .0369) and dyslipidemia (p ¼ .0092)
(Table 5). Furthermore, hospital stay was signiﬁcantly
shorter for patients treated with PTA  stent þ UK
(Table 1).Number of arterial lesion sites receiving vascular
intervention
The number of lesion sites receiving vascular interventions
was calculated using a ﬁve-item score according to the ﬁveTable 2B. Relationship between the number of arterial lesion sites rec
No. of arterial lesions receiving intervention PTA  stent, n ¼ 85 (
1 29.4
2 37.6
3 25.8
4 7.0
5 0
Note. PTA ¼ percutaneous transluminal angioplasty; UK ¼ urokinase.
a Fisher’s exact test.arterial sites. A score of 0 was assigned if no procedure was
performed on any of the ﬁve arterial sites (iliac, femoral,
ATa, PTa, or peroneal arteries; <50% stenosis), while a
score of 1 was assigned to every lesion site receiving
vascular intervention. The sum of scores determined the
total arterial lesion sites receiving treatment. Based on the
number of arterial lesion sites receiving vascular interven-
tion, there was no signiﬁcant difference in the average
number of interventions between treatment groups
(PTA  stent 2.11; PTA  stent þ UK 2.27; p ¼ .2482).
Overall, there was no between-group signiﬁcant difference
when the patients were distributed and statistically evalu-
ated according to the number of arterial lesion sites
receiving vascular intervention (p ¼ .3052) (Table 2).Safety
Access puncture site skin ecchymosis was reported in
approximately 30% of patients in both groups. Three SAEs
(on patient with intracranial hemorrhage and two patients
with bleeding at the inguinal puncture site) were reported
in the PTA  stent þ UK group. There were no cases of
gastrointestinal bleeding or hematuria in either group. One
(1.1%) death was reported in the PTA  stent þ UK group
(acute myocardial infarction [AMI]) and there were seven
(8.2%) deaths in the PTA  stent group (three AMIs, two
CVAs, one sepsis, one gastrointestinal bleeding). There were
no intraoperative deaths, and all deaths were regarded as
perioperative as they occurred during the hospital stay after
intervention.
DISCUSSION
This study evaluated the effect of systemic UK administra-
tion daily for 5 days after a PTA  stent procedure on limb
salvage rate in patients with CLI with tissue loss (Rutherford
stage 5 or 6 and Fontaine stage 4).1,10,11 The mean (SD)
baseline ABI values for the PTA  stent and
PTA  stent þ UK groups were comparable, although
elevated owing to severe calciﬁcation of vessels in several
patients. Furthermore, the groups were comparable in
terms of comorbidities and baseline ABI. The results showed
a statistically signiﬁcant reduction in the rate of major
amputations in the PTA  stent þ UK group compared with
the PTA  stent group.
There was a signiﬁcant reduction in hospital stay for UK-
treated patients, which is a good indication of reduction in
wound healing time with the provision of inpatient care for
wound and surgical debridement.eiving vascular intervention.
%) PTA  stent þ UK, n ¼ 90 (%) Total, n ¼ 175 (%) pa
18.8 24.0 .3052
47.7 42.9 e
22.2 24.0 e
10.0 8.6 e
1.1 .6 e
Table 3. Levels of amputation in all patients stratiﬁed as minor (direct wound healing/no amputation or minor surgical debridement or
minor toes amputation) and major (below-knee amputation stump ¼ 10 cm, or above-knee amputation).
All patients, n (%) Level of amputation
Minor Major Total p (odds ratio)a
PTA  stent 65/151 (43.0) 20/24 (83.3) 85/175 (48.6) .0003 (6.6154)
PTA  stent þ UK 86/151 (57.0) 4/24 (16.7) 90/175 (51.4) e
Note. PTA ¼ percutaneous transluminal angioplasty; UK ¼ urokinase.
a p < .05 was considered to be statistically signiﬁcant.
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patients with subacute or chronic occlusions with signiﬁcant
clot load. Patients with TransAtlantic InterSociety Consensus
C and D lesions undergoing endovascular intervention for
seemingly nonacute occlusions with high clot load in the
iliac arteries and SFA had increased movement of several
clots downstream, associated with a corresponding wors-
ening of symptoms, reported retrospectively.
PTA is an intervention that can be combined with local
thrombolysis for acute and chronic occlusions.1,12e14 During
balloon angioplasty in the femoropopliteal region, down-
stream embolization of ﬁbrin aggregates is a common
event. Konig et al.6 reported the presence of micro-
embolization after each procedure, and that macro-
embolization was more frequent than has been previously
reported. Furthermore, “natural” microembolism is also
known to occur prior to PTA.15 Therefore, we considered
the administration of UK after the PTA  stent
procedure, which might help resolve possible micro- or
macroembolism.
The efﬁcacy of thrombolysis decreases as the duration
progressively increases from acute to subacute to chronic
occlusions,5 suggesting that the efﬁcacy of thrombolyticFigure 1. Distribution of the level of amputation between the
treatment groups. The y-axis represents the number of patients;
open bars represent the group treated with percutaneous trans-
luminal angioplasty (PTA) with or without stenting followed by
urokinase (UK) infusion for 5 days (PTA  stent þ UK) group; and
the closed bars represent the PTA  stent group. The level of
amputation is presented as minor (direct wound healing or no
amputation or minor surgical debridement or minor toes ampu-
tation) and major (below-knee amputation [below-knee stump,
10 cm] or above-knee amputation, or amputation with mortality
caused by underlying disease).therapy may be dependent on the duration of the lesion;
however, the complications of the intervention in terms of
clot load and the procedure itself (embolism and local
thrombosis) may be phasic and can be anticipated. The
reduction in major amputations noted in this study
following daily IV infusion of UK for 5 days in the post-
PTA  stent phase could be attributed to a reduction in
these anticipated complications.
Suggs et al.16 showed that thrombolysis with UK as the
sole therapy in 18 patients (29%) or as a valuable adjunct
that facilitated angioplasty of arterial lesions was able to
avoid the need for open surgery in 60% of the treated pa-
tients. This reduction in the requirement of subsequent
bypass procedures was found to be beneﬁcial in terms of
limb salvage, particularly in patients with new-onset clau-
dication, suggesting that the treatment for peripheral artery
disease (PAD) should be as conservative as possible.16
Similarly, an open-label, prospective, uncontrolled,
multicenter cohort study in 77 diabetic patients with CLI
and foot ulceration evaluated the effect of IV infusion of UK
for a longer duration (>30 minutes daily) of 21 days. The
results showed that, at the 1-year follow-up, 25 patients
(33%) had completely healed ulcers with no major ampu-
tation, 53 patients (69%) survived without major amputa-
tion, and the rate of major amputation was 21%. It was
concluded that UK was effective in reducing the require-
ment of major amputation in patients with diabetic foot.8
Besides diabetic foot, there is increasing interest in
extending the application of UK to the perioperative treat-
ment of borderline amputations.9 In the present study, after
administering UK for 5 days, there was an increase in the
number of patients who underwent minor amputation and
a decrease in the number of patients who underwent major
amputation. Although there were signiﬁcantly (p ¼ .0251)
more patients with diabetes in the PTA  stent group,
when patients with diabetes were equally distributed in
both groups (47 patients each) there was a signiﬁcant
(p ¼ .0051) reduction in major amputations.
Currently, PTA is regarded as the treatment of choice for
infrapopliteal occlusive disease; however, available data on
the use of stents in this area are insufﬁcient to justify its
primary use.17,18 In addition, it should be noted that,
despite patent endovascularly treated arterial segments,
there is evidence major amputation may still be required in
patients with CLI. This is postulated to be the result of
aggressive attempts at limb salvage, and is likely to affect
patients with diabetes and gangrene who undergo infra-
popliteal interventions.19 Furthermore, the literature sug-
gests that outcomes (amputation-free survival, overall
Table 4. Levels of amputation evaluated according to the intervention received at the arterial lesion site.
Arterial site with lesion, receiving intervention, n (%)
Level of amputation
Arterial lesion site UK used? Minor Major Total pa
Iliac 1 Yes 5.8 (62.5) 1/6 (16.7) 6/14 (42.9) .2308
No 3.8 (37.5) 5/6 (83.3) 8/14 (57.1)
2 Yes 0/1 (0.0) 1/2 (50) 1/3 (33.3) 1.0000
No 1/1 (100) 1/2 (50) 2/3 (66.7)
Femoral 1 Yes 26/37 (70.3) 2/13 (15/4) 28/50 (56.0) .0008
No 11/37 (29.7) 11/13 (84.6) 22/50 (44.0)
2 Yes 15/28 (53.6) 2/10 (20.0) 17/38 (44.7) .3211
No 13/28 (46.4) 8/10 (80.0) 21/38 (55.3)
ATa 2 Yes 28/46 (60.9) 1/8 (12.5) 29/54 (53.7) .0395
No 18/46 (39.1) 7/8 (87.5) 25/54 (46.3)
PTa 2 Yes 19/29 (65.5) 2/9 (22.2) 25/54 (46.3) .0203
No 10/29 (34.5) 7/9 (77.8) 17/38 (44.7)
Peroneal 2 Yes 17/23 (73.9) 0/5 (0) 17/28 (60.7) .0047
No 6/23 (26.1) 5/5 (100) 11/28 (39.3)
Arterial site without lesion, not receiving any intervention, n (%)
Level of amputation
Arterial site with no lesion UK used? Minor Major Total p
Iliac 0 Yes 43/70 (61.4) 2/16 (12.5) 45/86 (52.3) .0011
No 27/70 (38.6) 14/16 (87.5) 41/86 (47.7) ND
Femoral 0 Yes 7/14 (50.0) 0/1 (0) 7/15 (46.7) ND
No 7/14 (50.0) 1/1 (100) 8/15 (53.3)
ATa 0 Yes 20/33 (60.6) 3/16 (18.8) 23/49 (46.9) .0366
No 13/33 (39.4) 13/16 (81.3) 26/49 (53.1)
PTa 0 Yes 29/50 (58.0) 2/15 (13.3) 31/65 .0218
No 21/50 (42.0) 3/15 (86.7) 34/65 (52.3)
Peroneal 0 Yes 31/56 (55.4) 4/19 (21.1) 35/75 (46.7) .0614
No 25/56 (44.6) 4/19 (21.1) 35/75 (46.7)
Note. 0 ¼ lesion not requiring any intervention (<50% stenosis); 1 ¼ placement of stent; 2 ¼ balloon angioplasty only. Minor
amputation ¼ direct wound healing/no amputation or minor surgical debridement or minor toes amputation; major
amputation ¼ below-knee amputation (stump ¼ 10 cm) or above-knee amputation.ATa ¼ anterior tibial artery; PTa ¼ posterior tibial
artery; ND ¼ not determined.
a Fisher’s exact test. p < .05 was considered to be statistically signiﬁcant.
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after bypass following failed endovascular interventions are
worse when compared with patients who did not receive
previous interventions.20,21 One of the mechanisms pro-
posed for this observation is the loss of runoff vessels
during the endovascular interventions.22 The patients in
the present study had CLI with ischemic wounds, and all
lesions in the infrapopliteal region (ATa and PTa) were
treated with PTA (n ¼ 66) or PTA þ UK (n ¼ 82). As there
were a large number of lesions, the use of IV UK with PTA
proved to be a safer, and better, option for reducing the
level of amputation. This was also reﬂected in the increase
in rate of minor amputations in the group of patients
treated with UK.
In this study, there was a comparable distribution of ac-
cess puncture site skin ecchymosis in both groups, probably
related to concomitant anticoagulant and antiplatelet
medication. The three SAEs reported in the PTA 
stent þ UK group could be related to a lower rate of
transfusion of UK with a longer duration of exposure. There
was one death in the PTA  stent þ UK group compared
with seven in the PTA  stent group. This difference couldbe attributed to the reduction in cardiovascular events and
CVA with the use of UK.
This preliminary observational study had certain limita-
tions, including the exclusion of patients with recent CVA (6
months) and gastrointestinal bleeding episodes (3 months),
and that the administration of UK was initiated after 50
patients had been treated with PTA  stent. Furthermore,
the duration of symptoms in this cohort of patients with CLI
with tissue loss was not known; an ABI of <0.7 was
considered as an inclusion criterion for this cohort; runoff
status was assessed only clinically after the interventional
procedure; a routine angiogram was not performed to
evaluate vessel patency after the PTA  stent  UK pro-
cedure; and patient limb status was only evaluated clini-
cally. Repeat angiography to treat occlusion was limited to
some patients with poor wound healing or pulse loss.
Moreover, Doppler scans and skin perfusion measurements
were evaluated only at a late stage in patients with poor
wound healing or pulse loss.
In conclusion, given these study limitations, daily
administration of UK for 5 days after PTA  stent might
reduce the requirement for major amputations and thus
Table 5. Level of amputation evaluated by the presence or absence of comorbid conditions.
Presence of comorbid conditions, n (%)
Level of amputation
Disease UK used? Minor Major Total pa
DM Yes 43/72 (59.7) 4/22 (18.2) 47/94 (50.0) .0051
No 29/72 (40.3) 18/22 (81.8) 47/94 (50.0)
HTN Yes 48/78 (61.5) 4/24 (16.7) 52/102 (51.0) .0009
No 30/78 (38.5) 20/24 (83.3) 50/102 (49.0)
ESRD Yes 19/30 (63.3) 1/11 (9.1) 20/41 (48.8) .0063
No 11/30 (36.7) 10/11 (90.9) 21/41 (51.2)
CAD Yes 21/32 (65.6) 2/17 (11.8) 23/49 (46.9) .0023
No 11/32 (34.4) 15/17 (88.2) 26/49 (53.1)
CVA Yes 10/20 (50.0) 1/12 (8.3) 11/32 (34.4) .0694
No 10/20 (50.0) 11/12 (91.7) 21/32 (65.6)
Dyslipidemia Yes 30/48 (62.5) 4/15 (26.7) 34/63 (54.0) .0938
No 18/48 (37.5) 11/15 (73.3) 29/63 (46.0)
Absence of comorbid condition, n (%)
Level of amputation
Disease UK used? Minor Major Total pa
DM Yes 5/7 (71.4) 0/2 (0.0) 5/9 (55.6) .1667
No 2/7 (28.6) 2/2 (100) 4/9 (44.4)
HTN Yes 0/1 (0.0) 0/0 (0.0) 0/1 (0.0) ND
No 1/1 (100) 0/0 (0.0) 1/1 (100)
ESRD Yes 29/49 (59.2) 3/13 (23.1) 32/62 (51.6) .0626
No 20/49 (40.8) 10/13 (76.9) 30/62 (48.4)
CAD Yes 27/47 (57.4) 2/7 (28.6) 29/54 (53.7) .4876
No 20/47 (42.6) 5/7 (71.4) 25/54 (46.3)
CVA Yes 38/59 (64.4) 3/12 (25.0) 41/71 (57.7) .0369
No 21/59 (35.6) 9/12 (75.0) 30/71 (42.3)
Dyslipidemia Yes 18/31 (58.1) 0/9 (0.0) 18/40 (45.0) .0092
No 13/31 (41.9) 9/9 (100) 22/40 (55.0)
Note. Minor amputation ¼ direct wound healing/no amputation or minor surgical debridement or minor toe amputation; major
amputation ¼ below-knee amputation (stump ¼ 10 cm) or above-knee amputation.UK ¼ urokinase; DM ¼ diabetes mellitus;
HTN ¼ hypertension; ESRD ¼ end-stage renal disease; CAD ¼ coronary artery disease; CVA ¼ cerebrovascular accident; ND, not
determined.
a Fisher’s exact test. p < .05 was considered to be statistically signiﬁcant.
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tissue loss, which frequently requires additional operations
for aggressive revascularization. Furthermore, a majority of
the lesions (especially in the infrapopliteal region) were
treated with PTA or PTA þ UK; therefore, the improvement
in the limb salvage rate supports the fact that the focus of
treatment in patients with PAD should be as conservative as
possible. Additionally, lesions requiring no intervention
showed a signiﬁcant improvement in the amputation level
with UK. The addition of UK is a conservative approach and
might beneﬁt patients with CLI (with or without interven-
tion) involving the lower extremity. This beneﬁt could be
attributed to the prevention of postprocedural complica-
tions anticipated against the backdrop of the disease pro-
cess interacting with comorbid conditions in an ischemic
environment. However, these preliminary results need to be
conﬁrmed in an ongoing randomized prospective study.
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